Towards the Development of a Conceptual Framework of the Determinants of Pre-eclampsia: A Hierarchical Systematic Review of Biomarkers.

Background

Pre-eclampsia is a leading cause of maternal and perinatal morbidity and mortality. There are several determinants of individual pregnant women's risk of developing pre-eclampsia, including biomarkers and ultrasound markers.

Objective

A conceptual framework to collate and summarise the extensive body of literature on biomarkers (including ultrasound markers) associated with pre-eclampsia, through a hierarchical systematic literature review.

Search strategy

Medline, Embase, Health Technology Assessments, Database of Abstracts of Reviews of Effects, Cochrane Library were searched until April 2024.

Selection criteria

Reviews and cohort studies (> 100 participants) reporting biomarkers associated with pre-eclampsia were included.

Data collection and analysis

Studies were screened by title, then abstract and full text. Evidence was prioritised from umbrella reviews, followed by systematic reviews and then observational studies. Associations were assessed for strength of association and quality of evidence using GRADE.

Main results

The biomarker domain included 40 individual determinants of pre-eclampsia. Of these, there were 18 biomarkers with definite or probable associations based on moderate-strong quality evidence across markers of angiogenic imbalance, fetal-placental unit function, inflammatory and immune markers, and physiological markers. Vascular endothelial growth factor, human chorionic gonadotropin, inhibin-A, maternal serum placental protein-13, and interferon-gamma had definite associations based on high-quality evidence.

Conclusion

Biomarkers associated with the development of pre-eclampsia highlight the multi-factorial aetiology of the syndrome. The addition of biomarkers, including ultrasound, will optimise the prediction of pre-eclampsia and enable individualised risk stratification.

References:

• M. A. Brown, L. A. Magee, L. C. Kenny, et al., “Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice,” Hypertension 72, no. 1 (2018): 24–43.
• L. A. Magee, K. H. Nicolaides, and P. von Dadelszen, “Preeclampsia,” New England Journal of Medicine 386, no. 19 (2022): 1817–1832.
• L. Bellamy, J. P. Casas, A. D. Hingorani, and D. J. Williams, “Pre‐Eclampsia and Risk of Cardiovascular Disease and Cancer in Later Life: Systematic Review and Meta‐Analysis,” BMJ 335, no. 7627 (2007): 974.
• K. J. Chang, K. M. Seow, and K. H. Chen, “Preeclampsia: Recent Advances in Predicting, Preventing, and Managing the Maternal and Fetal Life‐Threatening Condition,” International Journal of Environmental Research and Public Health 20, no. 4 (2023): 2994.
• M. Rybak‐Krzyszkowska, J. Staniczek, A. Kondracka, et al., “From Biomarkers to the Molecular Mechanism of Preeclampsia—A Comprehensive Literature Review,” International Journal of Molecular Sciences 24, no. 17 (2023): 13252.